HCW Biologics Inc. (HCWB) News
Filter HCWB News Items
HCWB News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest HCWB News From Around the Web
Below are the latest news stories about HCW BIOLOGICS INC that investors may wish to consider to help them evaluate HCWB as an investment opportunity.
HCW Biologics Reports Third Quarter 2023 Financial Results And Recent Business HighlightsMIRAMAR, Fla., Nov. 14, 2023 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and age-related diseases, today reported financial results and recent business highlights for its third quarter ended September 30, 2023. A human data readout from the ongoing Phase 1 clinical trial to evaluate |
Investigator Sponsor of HCW Biologics’ Phase 1 Clinical Trial Presented Human Data Readout and Anti-Cancer Mechanism of Action of HCW9218 at 38th SITC Annual MeetingShowed HCW9218 clinical safety and tumor response endpointsfor 15 patients with heavily pretreated advanced solid tumors Results in ovarian cancer patients outpace other indications, with 66% stable disease MIRAMAR, Fla., Nov. 08, 2023 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and |
Masonic Cancer Center, University of Minnesota to Present Data in Poster Presentation Human Data Readout for Phase 1 Study to Evaluate HCW9218 in Solid Tumors at SITC 38th Annual MeetingHCW9218 is the lead product candidate of HCW Biologics Inc.MIRAMAR, Fla., Nov. 01, 2023 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and age-related diseases, will have a human data readout at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (“SITC”) from an ongoing |
Insider Buying: CFO Rebecca Byam Acquires 5,000 Shares of HCW Biologics IncOn September 13, 2023, Rebecca Byam, the Chief Financial Officer (CFO) of HCW Biologics Inc (NASDAQ:HCWB), made a significant insider purchase of 5,000 shares of the company's stock. |
Insider Buying: CFO Rebecca Byam Acquires 10,000 Shares of HCW Biologics IncOn September 12, 2023, Rebecca Byam, the Chief Financial Officer (CFO) of HCW Biologics Inc (NASDAQ:HCWB), made a significant insider purchase of 10,000 shares of the company's stock. |
HCW Biologics Participating at H.C. Wainwright 25th Annual Global Investment Conference in New York on September 11 – 13, 2023Company will provide an update for clinical development and intellectual property programs, Including recent achievements and expected milestones in the next 12 monthsMIRAMAR, Fla., Sept. 06, 2023 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and age-related diseases, will participate |
Insider Stock Buying Reaches US$845k On HCW BiologicsGenerally, when a single insider buys stock, it is usually not a big deal. However, when several insiders are buying... |
HCW Biologics Reports Second Quarter 2023 Financial Results and Recent Business HighlightsMIRAMAR, Fla., Aug. 11, 2023 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and age-related diseases, today reported financial results and recent business highlights for its second quarter ended June 30, 2023. “During the period ended June 30, 2023, we have made significant progress in |
The past year for HCW Biologics (NASDAQ:HCWB) investors has not been profitableHCW Biologics Inc. ( NASDAQ:HCWB ) shareholders will doubtless be very grateful to see the share price up 56% in the... |
HCW Biologics is Granted Third Fundamental Patent: U.S. Patent for Methods of Treating Age-Related DisordersAllowed Methods of Use Claims Directed to Administering HCW9218 to Treat Cancer, Including Killing or Reducing the Number of Senescent Cells in Subjects with CancerMIRAMAR, Fla., June 14, 2023 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (“HCW Biologics” or the “Company”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between chronic, low-grade inflammation and age-related diseases, wa |